is acting as the sole financial adviser to Almirall on the transaction with
AstraZeneca regarding the rights to Almirall's respiratory franchise, for a
consideration of up to US$2.1 billion, plus profit shares and royalties.
includes an upfront payment of US$875 million and up to US$1.2 billion in
development, launch, and sales-related milestones.